Alkermes plc (ALKS) vs Arrowhead Pharmaceuticals, Inc. (ARWR)

A side-by-side comparison of Alkermes plc and Arrowhead Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ALKS vs ARWR

growth of $100 · dividends reinvested · last 10y
ALKS +1.1% (+0.1%/yr)ARWR +839.0% (+25.1%/yr)ARWR compounded faster over this window
Log scale — wide-divergence pair
101001k10kStart $10020182020202220242026$101$939
ALKS ARWR

ALKS vs ARWR: by the numbers

  • •ARWR is the larger company ($8.77B vs $7.00B market cap).
  • •ALKS is profitable (3.97% net margin) while ARWR runs a net loss (-47.79%).
  • •ARWR grew revenue faster over the past five years (44.14% vs 8.68% CAGR).

Metrics side by side

Valuation

MetricALKSARWR
P/E ratio108.98N/A
P/S ratio4.2013.09
P/B ratio3.8718.83
EV / EBITDA45.07N/A
FCF yield3.16%N/A

Profitability

MetricALKSARWR
Gross margin84.56%100.00%
Operating margin17.21%11.86%
Net margin3.97%-47.79%
ROE3.66%-68.73%
ROIC2.12%-12.12%

Growth (annualized)

MetricALKSARWR
Revenue CAGR (5Y)8.68%44.14%
FCF CAGR (5Y)20.00%N/A
Total return CAGR (5Y)6.73%0.75%

Frequently asked

Which has grown faster, ALKS or ARWR?
Over the past five years, ARWR grew revenue faster — ALKS at a 8.68% CAGR versus ARWR at 44.14%.
Is ALKS or ARWR more profitable?
ALKS runs the higher net margin — ALKS at 3.97% versus ARWR at -47.79%.
How have ALKS and ARWR total returns compared?
Over the past 10 years, ALKS delivered -0.82% and ARWR delivered 23.56% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.